摘要
在过去的10年,小分子核糖核酸已经广泛地引起科学家的注意力,因为肿瘤抑制剂或肿瘤发展过程中的致癌基因,转移以及对各种肿瘤治疗的内在抗性。小分子核糖核酸21表现出潜在的致癌功能以及几乎在所有的肿瘤中能够靶向肿瘤抑制蛋白。在细胞增殖、转移、侵略以及转移、细胞凋亡方面对小分子核糖核酸21的过度表达进行了研究。目前已经发展了不同规格、形状和成分的各种纳米级别的载体使用反义技术来抑制小分子核糖核酸的表达,来客服小分子核糖核酸的表达。小分子核糖核酸21反义寡核苷酸引用到肿瘤细胞的治疗已经是一种有潜力的治疗方案。此外,小分子核糖核酸21能够介导对放射和化学的抵抗性。本文也讨论了miR-21在人类肿瘤上扩展作用,强调了其调节靶点和机制。
关键词: 小分子核糖核酸21,肿瘤,靶向蛋白质,化学/放射抵抗性,致癌靶点
Current Gene Therapy
Title:miR-21, An Oncogenic Target miRNA for Cancer Therapy: Molecular Mechanisms and Recent Advancements in Chemo and Radio-resistance
Volume: 16 Issue: 6
关键词: 小分子核糖核酸21,肿瘤,靶向蛋白质,化学/放射抵抗性,致癌靶点
摘要: In the past decade, miRNAs have been extensively attracted the scientist’s attentions as tumor suppressors or oncogenes that have been implicated in tumor progression, metastasis and intrinsic resistance to various cancer therapies. microRNA-21 (miR-21) demonstrates a potential oncogenic function and targets tumor inhibitor proteins in almost all types of cancer. miR-21 overexpression has been studied in terms of cell proliferation, migration, invasion, metastasis, and apoptosis regulation. Inhibition of miRNA expression using antisense technology by various nanovectors of different sizes, shapes and compositions has been evolved progressively to overcome the barriers confronted by miRNA delivery. Application of miR-21 antisense oligonucleotides for treating cancerous cells has become a promising achievement for cancer therapy. Moreover, miR-21 can mediate resistance to radiation and chemotherapy. The expanding role of miR-21 functions in human cancers with an emphasis on its regulatory targets and mechanisms, miR-21 related achievements against cancer promotion have been discussed.
Export Options
About this article
Cite this article as:
miR-21, An Oncogenic Target miRNA for Cancer Therapy: Molecular Mechanisms and Recent Advancements in Chemo and Radio-resistance, Current Gene Therapy 2016; 16 (6) . https://dx.doi.org/10.2174/1566523217666170102105119
DOI https://dx.doi.org/10.2174/1566523217666170102105119 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
New Perspectives in Glioma Immunotherapy
Current Pharmaceutical Design The Wnt/Beta-Catenin Pathway in Wilms Tumors and Prostate Cancers
Current Molecular Medicine Fabrication of Multi-functionalized Gold Nanoparticles and the Application to Electrochemical Detection of Nitrite
Current Nanoscience Peptide-Receptor Ligands and Multivalent Approach
Anti-Cancer Agents in Medicinal Chemistry Heavy Metals and Epigenetic Alterations in Brain Tumors
Current Genomics An Overview of Acute Flaccid Myelitis
CNS & Neurological Disorders - Drug Targets Targeting Calcium Channels to Block Tumor Vascularization
Recent Patents on Anti-Cancer Drug Discovery Doxorubicin Sensitizes the Non-Small Cell Lung Cancer Cells to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Mediated (TRAIL) Apoptosis In Vitro but not In Vivo
Letters in Drug Design & Discovery Next Generation Tyrosine Kinase Inhibitor (TKI): Afatinib
Recent Patents on Anti-Cancer Drug Discovery Bone Morphogenetic Protein-Smad Pathway as Drug Targets for Osteoporosis and Cancer Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Heterocyclic Compounds as Anti-Inflammatory Agents
Current Bioactive Compounds Targeting Cancer Cells by an Oxidant-Based Therapy
Current Molecular Pharmacology Is there U-turn from Insulin Back to Pills in Diabetes?
Current Vascular Pharmacology Non-viral Delivery Systems for the Application in p53 Cancer Gene Therapy
Current Medicinal Chemistry Coupling of Conjugating Enzymes and Efflux Transporters: Impact on Bioavailability and Drug Interactions
Current Drug Metabolism Recent Progress in Discovery and Development of Antimitotic Agents
Anti-Cancer Agents in Medicinal Chemistry Intracellular Trafficking of MDR Transporters and Relevance of SNPs
Current Topics in Medicinal Chemistry Recent Advances in the Development of MMPIs and APNIs Based on the Pyrrolidine Platforms
Mini-Reviews in Medicinal Chemistry Cytokinin Nucleosides - Natural Compounds with a Unique Spectrum of Biological Activities
Current Topics in Medicinal Chemistry Carbon Nanotubes: An Emerging Drug Delivery Carrier in Cancer Therapeutics
Current Drug Delivery